| 產(chǎn)品編號(hào) | bs-1973R-BF350 |
| 英文名稱 | Rabbit Anti-Lipoprotein lipase/BF350 Conjugated antibody |
| 中文名稱 | BF350標(biāo)記的脂蛋白脂酶抗體 |
| 別 名 | Lipoprotein lipase; LIPD; LIPL_HUMAN; LPL; LPL protein; EC 3.1.1; EC 3.1.1.34; HDLCQ11; LPL; LPL protein; MGC137861. |
| 規(guī)格價(jià)格 | 100ul/2980元 購買 大包裝/詢價(jià) |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 心血管 細(xì)胞生物 免疫學(xué) 細(xì)胞粘附分子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, Mouse, Rat, (predicted: Pig, Cow, Rabbit, Sheep, Guinea Pig, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 52kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human LPL |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Lipoprotein lipase (LPL) is the central enzyme in plasma triglyceride hydrolysis and is secreted by macrophages in the subendothelial space. Evidence has been provided that LPL produced by macrophages in the vessel wall exerts proatherogenic effects. The atherogenic effects of LPL have been mainly attributed to its ability to favor lipid accumulation within macrophages present in the atherosclerotic lesion. Recently, it has also been shown that LPL promote the development of atherosclerosis through facilitation of monocyte adhesion to endothelial cells, stimulation of tumor necrosis factor alpha (TNF ) secretion and induction of vascular smooth muscle cell proliferation. Function: Actin-binding protein. Plays a role in the activation of T-cells in response to costimulation through TCR/CD3 and CD2 or CD28. Modulates the cell surface expression of IL2RA/CD25 and CD69. Subunit: Homodimer. Interacts with APOC2; the interaction activates LPL activity in the presence of lipids. Interacts with GPIHBP1. Subcellular Location: Cell membrane; Lipid-anchor, GPI-anchor. Secreted. Note=Locates to the plasma membrane of microvilli of hepatocytes with triacyl-glycerol-rich lipoproteins (TRL). Some of the bound LPL is then internalized and located inside non-coated endocytic vesicles. Tissue Specificity: Detected in intestinal microvilli, hair cell stereocilia, and fibroblast filopodia, in spleen and other lymph node-containing organs. Expressed in peripheral blood T lymphocytes, neutrophils, monocytes, B lymphocytes, and myeloid cells. Post-translational modifications: Tyrosine nitration after lipopolysaccharide (LPS) challenge down-regulates the lipase activity. DISEASE: Defects in LPL are the cause of lipoprotein lipase deficiency (LPL deficiency) [MIM:238600]; also known as familial chylomicronemia or hyperlipoproteinemia type I. LPL deficiency chylomicronemia is a recessive disorder usually manifesting in childhood. On a normal diet, patients often present with abdominal pain, hepatosplenomegaly, lipemia retinalis, eruptive xanthomata, and massive hypertriglyceridemia, sometimes complicated with acute pancreatitis. Similarity: Belongs to the AB hydrolase superfamily. Lipase family. Contains 1 PLAT domain. Database links: Entrez Gene: 4023 Human Entrez Gene: 16956 Mouse Omim: 238600 Human SwissProt: P06858 Human SwissProt: P11152 Mouse Unigene: 180878 Human Unigene: 1514 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 脂蛋白脂酶（lipoprteinlipase，LPL）是甘油三酯降解為甘油和游離脂肪酸 (FFA)反應(yīng)的限速酶,是脂肪細(xì)胞、心肌細(xì)胞、骨骼肌細(xì)胞、乳腺細(xì)胞以及巨噬細(xì)胞等實(shí)質(zhì)細(xì)胞合成和分泌的一種糖蛋白與機(jī)體的脂質(zhì)代謝及肥胖與否密切相關(guān). 近年來研究認(rèn)為：LPL可通過粘附作用，促進(jìn)了單核細(xì)胞血管內(nèi)皮細(xì)胞及腫瘤壞死因子（TNF）的分泌、血管平滑肌細(xì)胞增殖等因素，導(dǎo)致動(dòng)脈粥樣硬化的加重。 |
